
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3671085/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The hypodopaminergic state ten years after: transcranial magnetic stimulation as a tool to test the dopamine hypothesis of drug addiction. Current Opinion in Pharmacology, 2021, 56, 61-67.	3.5	15
2	Transcranial Magnetic Stimulation: A review about its efficacy in the treatment of alcohol, tobacco and cocaine addiction. Addictive Behaviors, 2021, 114, 106760.	3.0	38
3	Neurotoxicity of Exogenous Cannabinoids. , 2021, , 1-31.		1
4	Editorial: Novel Psychoactive Drugs—The Saga Continues…. Frontiers in Neuroscience, 2021, 15, 650518.	2.8	0
5	Gender-specific approach in psychiatric diseases: Because sex matters. European Journal of Pharmacology, 2021, 896, 173895.	3.5	18
6	Repeated exposure to JWHâ€018 induces adaptive changes in the mesolimbic and mesocortical dopaminergic pathways, glial cells alterations, and behavioural correlates. British Journal of Pharmacology, 2021, 178, 3476-3497.	5.4	12
7	New insights into methoxetamine mechanisms of action: Focus on serotonergic 5-HT2 receptors in pharmacological and behavioral effects in the rat. Experimental Neurology, 2021, 345, 113836.	4.1	4
8	Analysis of Opioid-Seeking Behavior Through the Intravenous Self-Administration Reinstatement Model in Rats. Methods in Molecular Biology, 2021, 2201, 231-245.	0.9	3
9	Conditioned Place Preference (CPP) in Rats: From Conditioning to Reinstatement Test. Methods in Molecular Biology, 2021, 2201, 221-229.	0.9	5
10	Novel halogenated synthetic cannabinoids impair sensorimotor functions in mice. NeuroToxicology, 2020, 76, 17-32.	3.0	23
11	Editorial: Sexual Behavior as a Model for the Study of Motivational Drive and Related Behaviors. Frontiers in Behavioral Neuroscience, 2020, 14, 121.	2.0	1
12	Sex and Gender Differences in the Effects of Novel Psychoactive Substances. Brain Sciences, 2020, 10, 606.	2.3	28
13	Editorial: The Therapeutic Potential of Transcranial Magnetic Stimulation in Addiction. Frontiers in Neuroscience, 2020, 14, 614642.	2.8	1
14	Neuronal and peripheral damages induced by synthetic psychoactive substances: an update of recent findings from human and animal studies. Neural Regeneration Research, 2020, 15, 802.	3.0	30
15	Repetitive transcranial magnetic stimulation: Re-wiring the alcoholic human brain. Alcohol, 2019, 74, 113-124.	1.7	10
16	Intermittent Theta Burst Stimulation of the Prefrontal Cortex in Cocaine Use Disorder: A Pilot Study. Frontiers in Neuroscience, 2019, 13, 765.	2.8	35
17	Editorial: Novel Psychoactive Drugs. Frontiers in Psychiatry, 2019, 10, 119.	2.6	5
18	The novel psychoactive substance methoxetamine induces persistent behavioral abnormalities and neurotoxicity in rats. Neuropharmacology, 2019, 144, 219-232.	4.1	19

#	Article	IF	CITATIONS
19	Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine. Psychopharmacology, 2018, 235, 433-445.	3.1	21
20	Old and new synthetic cannabinoids: lessons from animal models. Drug Metabolism Reviews, 2018, 50, 54-64.	3.6	20
21	Sex-specific differences in cannabinoid-induced extracellular-signal-regulated kinase phosphorylation in the cingulate cortex, prefrontal cortex, and nucleus accumbens of Lister Hooded rats. Behavioural Pharmacology, 2018, 29, 473-481.	1.7	8
22	Levodopa prevents the reinstatement of cocaine selfâ€administration in rats via potentiation of dopamine release in the medial prefrontal cortex. Addiction Biology, 2018, 23, 556-568.	2.6	10
23	Mediterranean Neuroscience Methods 2017. Journal of Neuroscience Methods, 2018, 310, 1-2.	2.5	1
24	Sex and Feeding Status Differently Affect Natural Reward Seeking Behavior in Olfactory Bulbectomized Rats. Frontiers in Behavioral Neuroscience, 2018, 12, 255.	2.0	7
25	The Modulating Role of Sex and Anabolic-Androgenic Steroid Hormones in Cannabinoid Sensitivity. Frontiers in Behavioral Neuroscience, 2018, 12, 249.	2.0	26
26	Therapeutic Use of Synthetic Cannabinoids: Still an Open Issue?. Clinical Therapeutics, 2018, 40, 1457-1466.	2.5	39
27	Taste novelty and dopamine. , 2018, , 147-165.		Ο
28	Sales and Advertising Channels of New Psychoactive Substances (NPS): Internet, Social Networks, and Smartphone Apps. Brain Sciences, 2018, 8, 123.	2.3	50
29	Neurological, sensorimotor and cardiorespiratory alterations induced by methoxetamine, ketamine and phencyclidine in mice. Neuropharmacology, 2018, 141, 167-180.	4.1	37
30	Sex differences in drug-induced psychosis. Current Opinion in Behavioral Sciences, 2017, 13, 152-157.	3.9	5
31	Methoxetamine affects brain processing involved in emotional response in rats. British Journal of Pharmacology, 2017, 174, 3333-3345.	5.4	21
32	The anabolic steroid nandrolone alters cannabinoid self-administration and brain CB1 receptor density and function. Pharmacological Research, 2017, 115, 209-217.	7.1	12
33	Synthetic cannabinoids: clinical aspects and therapy options. European Neuropsychopharmacology, 2017, 27, S575-S576.	0.7	Ο
34	Novel Psychoactive Substances. , 2017, , 341-353.		8
35	Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health. Frontiers in Psychiatry, 2017, 8, 156.	2.6	161
36	How CB1 Receptor Activity and Distribution Contribute to Make the Male and Female Brain Different Toward Cannabinoid-Induced Effects. , 2017, , 27-51.		6

#	Article	IF	CITATIONS
37	Editorial: Exploring Gender and Sex Differences in Behavioral Dyscontrol: From Drug Addiction to Impulse Control Disorders. Frontiers in Psychiatry, 2016, 7, 19.	2.6	8
38	Sex differences in impulsive and compulsive behaviors: a focus on drug addiction. Addiction Biology, 2016, 21, 1043-1051.	2.6	50
39	The ketamine analogue methoxetamine generalizes to ketamine discriminative stimulus in rats. Behavioural Pharmacology, 2016, 27, 204-210.	1.7	19
40	Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects: a review of case reports and preclinical findings. Behavioural Pharmacology, 2016, 27, 489-496.	1.7	26
41	The ketamine-like compound methoxetamine substitutes for ketamine in the self-administration paradigm and enhances mesolimbic dopaminergic transmission. Psychopharmacology, 2016, 233, 2241-2251.	3.1	22
42	Drug addiction: An affective-cognitive disorder in need of a cure. Neuroscience and Biobehavioral Reviews, 2016, 65, 341-361.	6.1	44
43	Elevated dopamine in the medial prefrontal cortex suppresses cocaine seeking via <scp>D</scp> 1 receptor overstimulation. Addiction Biology, 2016, 21, 61-71.	2.6	13
44	The novel cannabinoid antagonist SM-11 reduces hedonic aspect of food intake through a dopamine-dependent mechanism. Pharmacological Research, 2016, 113, 108-115.	7.1	12
45	The endocannabinoid system: possible new pharmacological target in the treatment of anorexia nervosa. European Neuropsychopharmacology, 2016, 26, S129.	0.7	0
46	Emotional profile of female rats showing binge eating behavior. Physiology and Behavior, 2016, 163, 136-143.	2.1	12
47	Synthetic Cannabinoids—Further Evidence Supporting the Relationship Between Cannabinoids and Psychosis. Biological Psychiatry, 2016, 79, 539-548.	1.3	131
48	Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives. Psychopharmacology, 2016, 233, 1765-1777.	3.1	39
49	Adolescent Δ9-Tetrahydrocannabinol Exposure Alters WIN55,212-2 Self-Administration in Adult Rats. Neuropsychopharmacology, 2016, 41, 1416-1426.	5.4	53
50	Reward processing and drug addiction: does sex matter?. Frontiers in Neuroscience, 2015, 9, 329.	2.8	15
51	Cannabinoids and drug addiction. , 2015, , 289-313.		1
52	Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat. Psychopharmacology, 2015, 232, 91-100.	3.1	15
53	Role of Opioid Receptors in the Reinstatement of Opioid-Seeking Behavior: An Overview. Methods in Molecular Biology, 2015, 1230, 281-293.	0.9	6
54	Analysis of Opioid-Seeking Reinstatement in the Rat. Methods in Molecular Biology, 2015, 1230, 295-307.	0.9	1

#	Article	IF	CITATIONS
55	Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms. Frontiers in Pharmacology, 2014, 5, 44.	3.5	32
56	Nicotine consumption is regulated by a human polymorphism in dopamine neurons. Molecular Psychiatry, 2014, 19, 930-936.	7.9	95
57	Sex differences in addictive disorders. Frontiers in Neuroendocrinology, 2014, 35, 272-284.	5.2	211
58	Δ9-Tetrahydrocannabinol Prevents Methamphetamine-Induced Neurotoxicity. PLoS ONE, 2014, 9, e98079.	2.5	22
59	The Role of the Endocannabinoid System in Eating Disorders: Neurochemical and Behavioural Preclinical Evidence. Current Pharmaceutical Design, 2014, 20, 2089-2099.	1.9	30
60	Male and Female Rats Differ in Brain Cannabinoid CB1 Receptor Density and Function and in Behavioural Traits Predisposing to Drug Addiction: Effect of Ovarian Hormones. Current Pharmaceutical Design, 2014, 20, 2100-2113.	1.9	108
61	Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats. Psychopharmacology, 2013, 225, 531-542.	3.1	21
62	Pharmacological modulation of the endocannabinoid signalling alters bingeâ€ŧype eating behaviour in female rats. British Journal of Pharmacology, 2013, 169, 820-833.	5.4	31
63	PPARα Regulates Cholinergic-Driven Activity of Midbrain Dopamine Neurons via a Novel Mechanism Involving α7 Nicotinic Acetylcholine Receptors. Journal of Neuroscience, 2013, 33, 6203-6211.	3.6	79
64	Molecular mechanisms of cannabinoid addiction. Current Opinion in Neurobiology, 2013, 23, 487-492.	4.2	36
65	Considering gender in cannabinoid research: A step towards personalized treatment of marijuana addicts. Drug Testing and Analysis, 2013, 5, 57-61.	2.6	34
66	Sex-specific tonic 2-arachidonoylglycerol signaling at inhibitory inputs onto dopamine neurons of Lister Hooded rats. Frontiers in Integrative Neuroscience, 2013, 7, 93.	2.1	47
67	The suppression of appetite and food consumption by methylphenidate: the moderating effects of gender and weight status in healthy adults. International Journal of Neuropsychopharmacology, 2012, 15, 181-187.	2.1	47
68	Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 234-243.	4.8	393
69	Beyond THC: The New Generation of Cannabinoid Designer Drugs. Frontiers in Behavioral Neuroscience, 2011, 5, 60.	2.0	360
70	Cannabinoid CB1 and Dopamine D1 Receptors Partnership in the Modulation of Emotional Neural Processing. Frontiers in Behavioral Neuroscience, 2011, 5, 67.	2.0	7
71	Differential effect of opioid and cannabinoid receptor blockade on heroinâ€seeking reinstatement and cannabinoid substitution in heroinâ€abstinent rats. British Journal of Pharmacology, 2011, 163, 1550-1562.	5.4	20
72	Cannabinoid-Opioid Interactions in Drug Discrimination and Self-Administration: Effect of Maternal, Postnatal, Adolescent and Adult Exposure to the Drugs. Current Drug Targets, 2010, 11, 450-461.	2.1	31

#	Article	IF	CITATIONS
73	Drug―and cueâ€induced reinstatement of cannabinoidâ€seeking behaviour in male and female rats: influence of ovarian hormones. British Journal of Pharmacology, 2010, 160, 724-735.	5.4	94
74	How important are sex differences in cannabinoid action?. British Journal of Pharmacology, 2010, 160, 544-548.	5.4	156
75	Peroxisome Proliferator-Activated Receptors-Alpha Modulate Dopamine Cell Activity Through Nicotinic Receptors. Biological Psychiatry, 2010, 68, 256-264.	1.3	92
76	The endocannabinoid system and nondrug rewarding behaviours. Experimental Neurology, 2010, 224, 23-36.	4.1	78
77	Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats. European Neuropsychopharmacology, 2010, 20, 25-36.	0.7	54
78	The Roman High- and Low-Avoidance Rat Lines Differ in the Acquisition, Maintenance, Extinction, and Reinstatement of Intravenous Cocaine Self-Administration. Neuropsychopharmacology, 2009, 34, 1091-1101.	5.4	85
79	Sex differences in the self-administration of cannabinoids and other drugs of abuse. Psychoneuroendocrinology, 2009, 34, S227-S236.	2.7	71
80	Baclofen prevents drug-induced reinstatement of extinguished nicotine-seeking behaviour and nicotine place preference in rodents. European Neuropsychopharmacology, 2009, 19, 487-498.	0.7	58
81	Sex Differences in Drug Addiction: A Review of Animal and Human Studies. Women's Health, 2008, 4, 51-65.	1.5	160
82	Neurobiological mechanisms of cannabinoid addiction. Molecular and Cellular Endocrinology, 2008, 286, S97-S107.	3.2	66
83	Crucial Role of α4 and α6 Nicotinic Acetylcholine Receptor Subunits from Ventral Tegmental Area in Systemic Nicotine Self-Administration. Journal of Neuroscience, 2008, 28, 12318-12327.	3.6	297
84	Inhibition of Anandamide Hydrolysis by Cyclohexyl Carbamic Acid 3′-Carbamoyl-3-yl Ester (URB597) Reverses Abuse-Related Behavioral and Neurochemical Effects of Nicotine in Rats. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 482-490.	2.5	132
85	Nicotinic Â7 Receptors as a New Target for Treatment of Cannabis Abuse. Journal of Neuroscience, 2007, 27, 5615-5620.	3.6	83
86	Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. Neuropharmacology, 2007, 52, 646-654.	4.1	67
87	The GABAB receptor agonist baclofen prevents heroin-induced reinstatement of heroin-seeking behavior in rats. Neuropharmacology, 2007, 52, 1555-1562.	4.1	60
88	Endocannabinoid regulation of relapse mechanisms. Pharmacological Research, 2007, 56, 418-427.	7.1	47
89	Cannabinoid selfâ€∎dministration in rats: sex differences and the influence of ovarian function. British Journal of Pharmacology, 2007, 152, 795-804.	5.4	172
90	Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. European Journal of Neuroscience, 2007, 25, 2191-2200.	2.6	74

#	Article	IF	CITATIONS
91	An endocannabinoid mechanism in relapse to drug seeking: A review of animal studies and clinical perspectives. Brain Research Reviews, 2007, 53, 1-16.	9.0	90
92	Cannabinoid self-administration increases dopamine release in the nucleus accumbens. NeuroReport, 2006, 17, 1629-1632.	1.2	101
93	Endocannabinoid system and opioid addiction: Behavioural aspects. Pharmacology Biochemistry and Behavior, 2005, 81, 343-359.	2.9	97
94	Cannabinoid CB1 antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology, 2005, 48, 1097-1104.	4.1	82
95	CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. British Journal of Pharmacology, 2004, 143, 343-350.	5.4	84
96	Cannabinoids and Reward: Interactions with the Opioid System. Critical Reviews in Neurobiology, 2004, 16, 147-158.	3.1	95
97	Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. European Journal of Neuroscience, 2003, 17, 1723-1726.	2.6	117
98	BACLOFEN ANTAGONIZES INTRAVENOUS SELF-ADMINISTRATION OF NICOTINE IN MICE AND RATS. Alcohol and Alcoholism, 2002, 37, 495-498.	1.6	88
99	Use of Biocytin as Neuroanatomic Tracer in Harvested Human Pancreas: A Confocal Laser Scanning Microscopy Analysis. Pancreas, 2002, 24, 329-335.	1.1	0
100	Astroglial in vivo response to cocaine in mouse dentate gyrus: a quantitative and qualitative analysis by confocal microscopy. Neuroscience, 2002, 110, 1-6.	2.3	101
101	Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behavioural Brain Research, 2001, 118, 61-65.	2.2	254
102	Functional Interaction between Opioid and Cannabinoid Receptors in Drug Self-Administration. Journal of Neuroscience, 2001, 21, 5344-5350.	3.6	347
103	Evidence of Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) in Pancreatic Islet Cells by Confocal Microscopy. Pancreas, 2001, 23, 68-71.	1.1	2
104	Baclofen antagonises intravenous self-administration of Î <sup>3</sup> -hydroxybutyric acid in mice. NeuroReport, 2001, 12, 2243-2246.	1.2	27
105	Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology, 2001, 156, 410-416.	3.1	180
106	Gamma-hydroxybutyric acid An evaluation of its rewarding properties in rats and mice. Alcohol, 2000, 20, 247-256.	1.7	26
107	The cyclo-oxygenase inhibitor nimesulide induces conditioned place preference in rats. European Journal of Pharmacology, 2000, 406, 75-77.	3.5	6
108	Role of Cannabinoid CB <sub>1</sub> Receptor in Morphine Rewarding Effects in Mice. Pharmacy and Pharmacology Communications, 2000, 6, 281-285.	0.3	5

#	Article	IF	CITATIONS
109	CB1 cannabinoid receptor agonist WIN 55,â€^212-2 decreases intravenous cocaine self-administration in rats. Behavioural Brain Research, 1999, 104, 141-146.	2.2	94
110	Gamma-Hydroxybutyric Acid Decreases Intravenous Cocaine Self-Administration in Rats. Pharmacology Biochemistry and Behavior, 1998, 59, 697-702.	2.9	12
111	Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience, 1998, 85, 327-330.	2.3	190
112	Intravenous self-administration of gamma-hydroxybutyric acid in drug-naive mice. European Neuropsychopharmacology, 1998, 8, 293-296.	0.7	43
113	Rewarding properties of gamma-hydroxybutyric acid: an evaluation through place preference paradigm. Psychopharmacology, 1997, 132, 1-5.	3.1	55